Seres Therapeutics, Inc.
MCRB
Last
$2.71
Day
+3.0%
1y
-86.5%
5y
-98.1%
52w
-91.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0424d
EMA 21
3.50
EMA 50
4.31
EMA 200
7.73
20d high
-48.9%
5y high
-98.9%
5y range
0th
Positions held
Your positionsMCRB isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$3.14
Stop
$2.20
Stop distance
18.8%
Target vs last
+15.9%
Fundamentals
| Market cap | $26.42M | Enterprise value | $67.20M | Trailing P/E | — | Forward P/E | -0.53 |
| PEG | — | Price / book | 0.75 | Beta | 0.31 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -21.0% |
| Profit margin | 0.0% | ROE | -66.6% | ROA | -39.8% | Debt / equity | 1.64 |
| Current ratio | 2.11 | Free cash flow | -$64.60M | Analyst recommendation | none | Mean target | $17.00 |
| 52w high | $29.98 | 52w low | $2.42 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | $0.4M | $0.8M | $0.0M | $0.0M | — |
| Op margin | -2101.4% | -5839.9% | -2455.9% | — | — | — |
| Net income | $4.6M | -$19.9M | -$15.3M | $8.2M | -$19.9M | — |
| Gross margin | 100.0% | 100.0% | 25.0% | — | — | — |
| Gross profit | $0.7M | $0.4M | $0.2M | -$0.7M | -$1.7M | — |
| Operating income | -$15.5M | -$20.9M | -$19.4M | -$22.5M | -$24.9M | — |
- Revenue +106% vs prior quarter ($0.7M vs $0.4M).
- Gross margin 100% (was 100% prior quarter).
- Operating margin expanded to -2101.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.8M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -11910.1% | — | — | — | — |
| Net income | $5.7M | $0.1M | -$114M | -$250M | — |
| Gross margin | -729.4% | — | — | — | — |
| Gross profit | -$5.8M | -$3.5M | $0.0M | $0.0M | — |
| Operating income | -$94.0M | -$121M | -$195M | -$180M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-08-13 · Seres Therapeutics Files $300 Million Mixed Shelf
2026-08-05 · Seres Therapeutics: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patternsMCRB · daily-34.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin